Definitive Contract HHSN261201200094C
Award Date 9/28/12
Potential Completion Date 3/27/15
Potential Value $747K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92129, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed Similar Awards
- This is a $999,996.00 definitive Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Avantgen Inc., a small business based in San Diego, California. The contract is for the development of recombinant rabbit monoclonal antibodies as affinity captures for peptides. Avantgen previously received other federal contracts and grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and National Cancer Institute for...
- This is a $149,951 federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency under the National Institutes of Health (NIH), to Avantgen Inc., a small business based in San Diego, California. The contract is for the development of recombinant antibodies as affinity captures, a specialized biotechnology service. The contract is a firm fixed price definitive contract with a completion date of May 28, 2011. This contract award was set aside for small business...
- This definitive contract was awarded by the National Institutes of Health National Cancer Institute to Avantgen Inc. for $299,854 to develop and validate non-mouse reagents to enable preclinical development of novel therapeutics under the Small Business Innovation Research Program Phase I solicitation. The contract responds to the research topic "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" listed in the NIH/CDC SBIR Contract...
- This is a $1,497,384.00 firm fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a small business biotechnology company based in San Diego, California. The contract is for the development of rabbit monoclonal antibodies for use as ferret biomarkers. This contract is not associated with a larger contract vehicle and does not have a set-aside designation. Avantgen Inc. has previously been awarded multiple federal...
- This is a $356,021 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies for ferret biomarkers. This work is set aside for small businesses. Avantgen has previously received NIH contracts to develop rapid diagnostic...
- This is a $1,995,852.00 Firm Fixed Price SBIR Phase II contract awarded by the National Cancer Institute (NCI) to Avantgen Inc., a small business based in San Diego, California. The contract is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" under Topic 372. The goal is to develop high-affinity, highly specific rabbit monoclonal antibodies against an expanded panel of 26 canine biomarkers to facilitate the use of dogs...
- This is a $592,751 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies to serve as biomarkers for the Indian Flying Fox (bat) virus. There is no set-aside designation for this contract. Avantgen has previously worked with NIAID and other federal agencies on the development of rapid test kits,...
- <p>This is a $1,999,386.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Avoneaux Medical Institute, LLC, a veteran-owned limited liability company. The contract is for the development of spatial micropurification technology under SBIR Topic 403. The contract is a definitive, firm fixed-price contract with a period of performance ending on September 18, 2024.</p>
- This is a $199,828 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to A&G Pharmaceutical, Inc. (doing business as Precision Antibody) for the development of "TECHNOLOGY GENERATED ANTI-PEPTIDE CAPTURE REAGENTS FOR AFFINITY ENRICHED PROTEOMIC STUDIES." The contract has a performance period ending on July 24, 2014 and was awarded on September 25, 2013. Precision Antibody is a for-profit...
- <p>This is a $200,000.00 definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Avidity Biosciences LLC, a for-profit limited liability company, on September 20, 2013. The contract is a firm fixed-price, set aside for small businesses. The work is to be performed in La Jolla, California and has a completion date of June 19, 2014. No additional details about the specific products or services to be provided under this contract were provided.</p>